UB Paderborn / Katalog / Suche / in CDI

26 – 50 von 82

Sortiert nach

Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade

Seminars in oncology, 2016-04, Vol.43 (2), p.222-232

2016

Link zum Volltext

Verfügbarkeit prüfen

MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia

Cancer research (Chicago, Ill.), 2017-12, Vol.77 (24), p.7038-7048

2017

Link zum Volltext

Verfügbarkeit prüfen

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model

Clinical cancer research, 2017-10, Vol.23 (19), p.5814-5823

2017

Link zum Volltext

Verfügbarkeit prüfen

Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia

Clinical cancer research, 2012-08, Vol.18 (15), p.4013-4018

2012

Link zum Volltext

Verfügbarkeit prüfen

Durable Responses to Single-Agent Ibrutinib in Monoallelic—but Not in Biallelic—TP53 Aberrated Patients with Chronic Lymphocytic Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.3111-3111

2018

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Reply

Clinical cancer research, 2016-07, Vol.22 (13), p.3412-3412

2016

Link zum Volltext

Verfügbarkeit prüfen

Pre-Clinical Modeling of Novel Therapeutics in Chronic Lymphocytic Leukemia: the Tools of the Trade

Seminars in oncology, 2016-02, Vol.43 (2), p.222-232

2016

Link zum Volltext

Verfügbarkeit prüfen

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Blood, 2019-11, Vol.134 (Supplement_1), p.1287-1287

2019

Link zum Volltext

Verfügbarkeit prüfen

Prolonged Field Care Research Approach and Its Relevance to Civilian Medicine

Military medicine, 2021-05, Vol.186 (5-6), p.123-128

2021

Link zum Volltext

Verfügbarkeit prüfen

3.23 Targeted Nanoparticle Delivery Overcomes Off-Target Immunostimulatory Effects of Oligonucleotides and Improves Therapeutic Efficacy

Clinical lymphoma, myeloma and leukemia, 2011-10, Vol.11, p.S213-S213

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia

Blood, 2013-01, Vol.121 (1), p.136-147

2013

Link zum Volltext

Verfügbarkeit prüfen

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

Blood, 2011-04, Vol.117 (16), p.4323-4327

2011

Link zum Volltext

Verfügbarkeit prüfen

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

Blood, 2012-08, Vol.120 (6), p.1262-1273

2012

Link zum Volltext

Verfügbarkeit prüfen

Transcriptome Analysis of the Lymph Node Microenvironment in Chronic Lymphocytic Leukemia

Blood, 2017-12, Vol.130, p.1718-1718

2017

Link zum Volltext

Verfügbarkeit prüfen

CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage

Leukemia & lymphoma, 2022-03, Vol.63 (4), p.911-917

2022

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.238-238

2018

Link zum Volltext

Verfügbarkeit prüfen

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

Blood, 2019-11, Vol.134 (Supplement_1), p.174-174

2019

Link zum Volltext

Verfügbarkeit prüfen

The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia

Blood advances, 2023-01, Vol.7 (1), p.145-158

2023

Link zum Volltext

Verfügbarkeit prüfen

Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia

Blood, 2017-12, Vol.130 (Suppl_1), p.799-799

2017

Link zum Volltext

Verfügbarkeit prüfen

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Blood, 2018-11, Vol.132 (Supplement 1), p.4424-4424

2018

Link zum Volltext

Verfügbarkeit prüfen

Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Blood, 2018-11, Vol.132 (Supplement 1), p.4401-4401

2018

Link zum Volltext

Verfügbarkeit prüfen

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Blood, 2018-11, Vol.132 (Supplement 1), p.186-186

2018

Link zum Volltext

Verfügbarkeit prüfen

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Blood, 2019-11, Vol.134 (Supplement_1), p.5474-5474

2019

Link zum Volltext

Verfügbarkeit prüfen

26 – 50 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(82)

Sprache

Englisch
(82)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Life Sciences & Biomedicine
(44)
Humans
(41)
Hematology
(28)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(26)
Oncology
(22)
Leukemia, Lymphocytic, Chronic, B-Cell - Pathology
(18)
Female
(17)
Male
(17)
Aged
(15)
Leukemia, Lymphocytic, Chronic, B-Cell - Genetics
(14)
Pyrimidines - Therapeutic Use
(14)
Lymphoid Neoplasia
(13)
Pyrazoles - Therapeutic Use
(13)
Animals
(12)
Leukemia, Lymphocytic, Chronic, B-Cell - Metabolism
(11)
Mice
(11)
Chronic Lymphocytic Leukemia
(10)
Pyrazoles - Pharmacology
(10)
Pyrimidines - Pharmacology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(52)
Clinical Cancer Research
(8)
Leukemia
(4)
Leukemia & Lymphoma
(4)
Cancer Cell
(2)
Cancer Research
(2)
Seminars In Oncology
(2)
Blood Advances
(1)
Clinical Lymphoma, Myeloma And Leukemia
(1)
Haematologica
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion

MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model

Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia

Durable Responses to Single-Agent Ibrutinib in Monoallelic—but Not in Biallelic—TP53 Aberrated Patients with Chronic Lymphocytic Leukemia

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Reply

Pre-Clinical Modeling of Novel Therapeutics in Chronic Lymphocytic Leukemia: the Tools of the Trade

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Prolonged Field Care Research Approach and Its Relevance to Civilian Medicine

3.23 Targeted Nanoparticle Delivery Overcomes Off-Target Immunostimulatory Effects of Oligonucleotides and Improves Therapeutic Efficacy

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

Transcriptome Analysis of the Lymph Node Microenvironment in Chronic Lymphocytic Leukemia

CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage

Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia

Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Suchergebnisse filtern